Plus Therapeutics presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium (186 Re) Obisbemeda in leptomeningeal disease (LM) at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting on November 25, 2024. A single intrathecal dose of Rhenium (186 Re) Obisbemeda showed a favorable response rate and median overall survival in LM patients.
The treatment achieved up to 8 times the absorbed radiation dose to the CNS subarachnoid space compared to standard of care external beam radiation. This highlights the targeted and potent delivery capabilities of the therapy.
The company also received FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186 Re) Obisbemeda for LM. This regulatory alignment supports the rapid advancement into further clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.